Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE REMUSAT : revenue, balance sheet and financial ratios

SELARL PHARMACIE REMUSAT is a French company founded 7 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75016), this company of category PME shows in 2024 a net income positive of 86 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Historique financier - SELARL PHARMACIE REMUSAT (SIREN 847885977)
Kennzahl 2024 2023 2022 2021 2020
Umsatz N/C N/C N/C N/C N/C
Nettoergebnis 85 751 € 43 608 € 244 995 € 206 585 € 95 874 €
EBITDA N/C N/C N/C N/C N/C
Nettomarge N/C N/C N/C N/C N/C

Umsatz und Gewinn- und Verlustrechnung

In 2024, SELARL PHARMACIE REMUSAT generates positive net income of 86 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2024: 96 k€ -> 86 k€.

Nettoergebnis (2024) ?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Formel
Ordentliches Ergebnis + Außerordentliches Ergebnis - Ertragsteuern

85 751 €

Chargement du compte de résultat...

Évolution graphique

Anzeigen :

Aktiva

Chargement des données...

Passiva

Chargement des données...

Solvenz- und Verschuldungskennzahlen

The debt ratio (= Financial debt / Equity x 100) stands at 222%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 26%. The balance between equity and debt is satisfactory.

Verschuldungsgrad (2024) ?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible
50-100% : Moderat
> 100% : Hoch

222.206%

Finanzielle Autonomie (2024) ?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Formel
(Eigenkapital / Bilanzsumme) x 100
Interpretation
> 30% : Gute Autonomie
20-30% : Durchschnitt
< 20% : Faible

26.247%

Anlagenaltersquote (2024) ?
Anlagenaltersquote
Definition
Misst den Abnutzungsgrad des Sachanlagevermögens.
Formel
Kumulierte Abschreibungen / Bruttoanlagevermögen x 100
Interpretation
< 50% : Neue Anlagen
50-70% : Normale Abnutzung
> 70% : Alternde Anlagen

48.5%

Entwicklung der Solvenzkennzahlen
SELARL PHARMACIE REMUSAT

Positionnement sectoriel

Debt ratio
222.21 2024
2022
2023
2024
Q1: 16.46
Méd: 58.48
Q3: 154.77
Average

In 2024, the debt ratio of SELARL PHARMACIE REMUSAT (222.21) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
26.25% 2024
2022
2023
2024
Q1: 28.91%
Méd: 49.95%
Q3: 69.47%
Watch

In 2024, the financial autonomy of SELARL PHARMACIE REMUSAT (26.2%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquiditätskennzahlen

The liquidity ratio (= Current assets / Current liabilities) stands at 184.34. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquiditätsquote (2024) ?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut
1-1.5 : Angemessen
< 1 : Risque de liquidité

184.345

Entwicklung der Liquiditätskennzahlen
SELARL PHARMACIE REMUSAT

Positionnement sectoriel

Liquidity ratio
184.34 2024
2022
2023
2024
Q1: 129.46
Méd: 182.14
Q3: 260.79
Good -24 pts über 3 Jahre

In 2024, the liquidity ratio of SELARL PHARMACIE REMUSAT (184.34) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Positionnement de SELARL PHARMACIE REMUSAT dans son secteur

Vergleich mit der Branche Commerce de détail de produits pharmaceutiques en magasin spécialisé

Bewertungsschätzung

Based on 225 transactions of similar company sales in 2024, the value of SELARL PHARMACIE REMUSAT is estimated at 1 197 147 € (range 833 674€ - 1 791 000€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
833k€ 1197k€ 1791k€
1 197 147 € Range: 833 674€ - 1 791 000€
NAF 5 année 2024

Valuation method used

Net Income Multiple
85 751 € × 14.0x = 1 197 147 €
Range: 833 674€ - 1 791 001€

Only this financial indicator is available for this company.

Bewertungsentwicklung

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE REMUSAT with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE REMUSAT

What is the revenue of SELARL PHARMACIE REMUSAT ?

The revenue of SELARL PHARMACIE REMUSAT is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE REMUSAT profitable?

Yes, SELARL PHARMACIE REMUSAT generated a net profit of 86 k€ in 2024.

Where is the headquarters of SELARL PHARMACIE REMUSAT ?

The headquarters of SELARL PHARMACIE REMUSAT is located in PARIS (75016), in the department Paris.

Where to find the tax return of SELARL PHARMACIE REMUSAT ?

The tax return of SELARL PHARMACIE REMUSAT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE REMUSAT operate?

SELARL PHARMACIE REMUSAT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.